Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Patient Educ Couns. 2018 Dec 10;102(5):976–983. doi: 10.1016/j.pec.2018.12.011

Fig. 3.

Fig. 3.

Trajectory during follow-up of concern about developing RA by Comparison arm or, among those in the PRE-RA or PRE-RA Plus arms, stratified by high (≥5%), or low (<5%) calculated lifetime RA risk results (n = 232).